<DOC>
	<DOCNO>NCT03063047</DOCNO>
	<brief_summary>This study evaluate exposure `` tar '' nicotine two menthol cigarette product provide basis compare mouth-level exposure smoker smoke two cigarette product . Mouth-level exposure measurement substance trap cigarette butt smoking cigarette . Other purpose study : - Compare plasma cotinine , byproduct body 's processing nicotine , level find user smoke two different cigarette . - Find daily mouth-level exposure cigarette `` tar '' nicotine smoke two different cigarette adult smoker . - Determine certain measure nicotine dependence change base type cigarette smoke - To compare product like intent use .</brief_summary>
	<brief_title>CSD1603 : A Crossover Study Evaluate Exposure `` Tar '' Nicotine From 100 Menthol Cigarette Products</brief_title>
	<detailed_description>The study consist one group approximately 32 adult subject randomly assign order smoke two study menthol cigarette product ( include one comparator product one test product ) . Subjects smoke study product exclusively approximately one week prior test visit , different product smoke week two-week period . Cigarette butt collect day prior test visit determination MLE `` tar '' nicotine level . Blood sample collect test visit determination plasma cotinine level . Subjects provide response question test visit ass cigarette smoke cigarette butt collection behavior precede day .</detailed_description>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Menthol</mesh_term>
	<criteria>Able read , understand , willing sign Informed Consent Form ( ICF ) . Generally healthy male female , 21 year age old , ScreeningEnrollment Visit . Selfreports smoke least seven cigarette per day inhale smoke . Usual brand cigarette one brand style specify . Smoked usual brand ≥ 3 month . Agrees exclusively smoke study cigarette smoke use tobacco nicotinecontaining product course study . Able read comprehend English . Able safely perform require study procedure , determine Investigator . Selfreported history heart disease , kidney disease , asthma lung disease , diabetes , liver disease , hypertension , hypercholesterolemia . At risk heart disease , i.e. , obesity ( body mass index [ BMI ] ≥ 40 kg/m2 ) , determine Investigator . Females ≥ 35 year age currently use systemic , estrogencontaining contraception , hormone replacement therapy . Postponing decision quit smoking ( define planning quit attempt within 30 day ScreeningEnrollment Visit ) participate study . Use medication substance aid smoke cessation , include limited nicotine replacement therapy ( NRT ) ( e.g. , nicotine gum , lozenge , patch ) , varenicline ( Chantix® ) , bupropion ( Wellbutrin® , Zyban® ) , lobelia extract within 30 day prior ScreeningEnrollment Visit . Females test positive pregnancy , pregnant breastfeeding , plan become pregnant course study . Determined Investigator inappropriate study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>